These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36873437)

  • 1. Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination.
    Czarnowska A; Kapica-Topczewska K; Tarasów E; Tarasiuk J; Chorąży M; Kochanowicz J; Kułakowska A
    Front Neurol; 2023; 14():1097799. PubMed ID: 36873437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?
    Gernert JA; Zimmermann H; Oswald E; Christmann T; Kümpfel T; Havla J
    Mult Scler Relat Disord; 2022 Nov; 67():104175. PubMed ID: 36126540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review.
    Matsumoto Y; Ohyama A; Kubota T; Ikeda K; Kaneko K; Takai Y; Warita H; Takahashi T; Misu T; Aoki M
    Front Neurol; 2022; 13():845755. PubMed ID: 35299613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of Multiple Sclerosis Uncovered Following Moderna SARS-CoV-2 Vaccination.
    Ahoussougbemey Mele A; Ogbuagu H; Parag S; Pierce B
    Cureus; 2022 Dec; 14(12):e32799. PubMed ID: 36694492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.
    Quintanilla-Bordás C; Gascón-Gimenez F; Alcalá C; Payá M; Mallada J; Silla R; Carratalà-Boscà S; Gasque-Rubio R; Castillo J; Casanova B
    Front Neurol; 2022; 13():897275. PubMed ID: 35572939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases.
    Nistri R; Barbuti E; Rinaldi V; Tufano L; Pozzilli V; Ianniello A; Marinelli F; De Luca G; Prosperini L; Tomassini V; Pozzilli C
    Front Neurol; 2021; 12():765954. PubMed ID: 34744992
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
    Smith JB; Gonzales EG; Li BH; Langer-Gould A
    JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
    Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
    Etemadifar M; Sigari AA; Sedaghat N; Salari M; Nouri H
    Hum Vaccin Immunother; 2021 Oct; 17(10):3481-3483. PubMed ID: 34015240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report.
    Osmanodja B; Schreiber A; Schrezenmeier E; Seelow E
    BMC Nephrol; 2021 Dec; 22(1):411. PubMed ID: 34895163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible neurological and brain MRI changes following COVID-19 vaccination: A case report.
    Rastogi A; Bingeliene A; Strafella AP; Tang-Wai DF; Wu PE; Mandell DM
    J Neuroradiol; 2022 Nov; 49(6):428-430. PubMed ID: 35381296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.
    Kaulen LD; Doubrovinskaia S; Mooshage C; Jordan B; Purrucker J; Haubner C; Seliger C; Lorenz HM; Nagel S; Wildemann B; Bendszus M; Wick W; Schönenberger S
    Eur J Neurol; 2022 Feb; 29(2):555-563. PubMed ID: 34668274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.
    Pugliatti M; Hartung HP; Oreja-Guevara C; Pozzilli C; Airas L; Alkhawajah M; Grigoriadis N; Magyari M; Van Wijmeersch B; Zakaria M; Linker R; Chan A; Vermersch P; Berger T
    Front Immunol; 2022; 13():1045101. PubMed ID: 36325318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    Fujimori J; Miyazawa K; Nakashima I
    J Neuroimmunol; 2021 Dec; 361():577755. PubMed ID: 34700047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 in a temporal relation to the onset of multiple sclerosis.
    Fragoso YD; Pacheco FAS; Silveira GL; Oliveira RA; Carvalho VM; Martimbianco ALC
    Mult Scler Relat Disord; 2021 May; 50():102863. PubMed ID: 33662859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of cases of CNS demyelination following COVID-19 vaccination.
    Ismail II; Salama S
    J Neuroimmunol; 2022 Jan; 362():577765. PubMed ID: 34839149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.